Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) in Patients with Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial.

Trial Profile

Cyclophosphamide, Doxorubicin, Vincristine, Prednisone plus Rituximab (CHOP-R) and Cyclophosphamide, Pixantrone, Vincristine, Prednisone plus Rituximab (CPOP-R) in Patients with Diffuse Large-B-cell Lymphoma: A Phase II, Randomized, Multicenter, Comparative Trial.

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 23 Jan 2015

At a glance

  • Drugs Pixantrone (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RAPID
  • Sponsors CTI BioPharma
  • Most Recent Events

    • 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
    • 07 Dec 2011 Results will be reported at the 2011 American Society of Hematology Annual Meeting, according to a Cell Therapeutics media release.
    • 08 Nov 2010 Planned End Date changed from 1 Nov 2010 to 1 Feb 2012 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top